SCHEMBL3598405

SCHEMBL3598405

CN(C)c1ccc(CCN2CCC(CNC(=O)O)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
CCR3 P51677 2/20 0.49
HTR4 Q13639 4/20 0.47
HTR2A P28223 3/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HRH3 Q9Y5N1 2/20 0.45
OPRM1 P35372 2/20 0.45
KCNH2 Q12809 2/20 0.45
CACNA1I Q9P0X4 1/20 0.45
GSK3B P49841 1/20 0.45
SLC22A1 O15245 1/20 0.45
NR1I2 O75469 1/20 0.45
ABCB1 P08183 1/20 0.45
CHRM1 P11229 1/20 0.45
DRD2 P14416 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
CHRM3 P20309 1/20 0.45
MAOA P21397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23123778 0.84 CCR3 (0.61) CCR3HTR4HTR2ASIGMAR1LTA4H
SCHEMBL3594346 0.81 LTA4H (0.55) L3MBTL1OPRM1GSK3BDRD3LTA4H
SCHEMBL3598407 0.79 OPRM1 (0.53) OPRM1KCNH2SLC22A1NR1I2ABCB1
SCHEMBL3938952 0.77 HRH3 (0.56) HRH3DRD2DRD4MAOBSIGMAR1
SCHEMBL2982100 0.77 CCR3 (0.42) L3MBTL1CCR3KDM4EALDH1A1HRH3
SCHEMBL3604725 0.76 LTA4H (0.60) GSK3BDRD2SIGMAR1LTA4HKDM1A
SCHEMBL23105175 0.76 HRH3 (0.71) L3MBTL1CCR3KDM4EALDH1A1HRH3
SCHEMBL27654942 0.76 SIGMAR1 (0.52) L3MBTL1KDM4EALDH1A1HRH3OPRM1
SCHEMBL3594120 0.75 MAPT (0.55) L3MBTL1HTR4HTR2AKDM4EALDH1A1
SCHEMBL5709528 0.75 KDM4E (0.45) HTR2AKDM4EALDH1A1HRH3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 L3MBTL1 4415/4885CCR3 1379/4885HTR4 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.